Thyroid cancer, breast cancer, gastric cancer, liver cancer, colorectal cancer, endometrial cancer, cervical cancer, prostate cancer
Conditions
Interventions
Normal group:None
Endometrial cancer group:None
Sponsors
Zhejiang Cancer Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Confirmed Cases: Patients histopathologically or cytologically diagnosed with thyroid cancer, breast cancer, gastric cancer, liver cancer, colorectal cancer, endometrial cancer, cervical cancer, or prostate cancer. 2. Complete Imaging Data: Availability of high-quality, protocol-compliant multimodal imaging records (e.g., chest X-ray, ultrasound, CT, MRI) acquired prior to or at the time of diagnosis. 3. Comprehensive Clinical Data: Matched baseline clinical information contemporaneous with imaging acquisition, including but not limited to age, sex, key laboratory biomarkers (e.g., AFP, PSA), and treatment regimens. 4. Full Disease Course Coverage: For prognostic prediction analysis, regular post-treatment imaging follow-up data and well-documented clinical endpoints (e.g., recurrence, metastasis, survival status). 5. Healthy Control Group: Individuals concurrently enrolled in health screenings, undergoing identical imaging protocols (e.g., chest X-ray), and confirmed free of malignant tumors through comprehensive medical evaluations. 6. Ethical Compliance: The study has received Institutional Review Board (IRB) approval from all participating centers. A waiver of informed consent will be requested for retrospective data, while prospective enrollment requires written informed consent.
Exclusion criteria
Exclusion criteria: 1. Poor Image Quality: Critical imaging data with severe artifacts, missing slice thickness parameters, or failing to meet the minimum quality requirements for model analysis. 2. Critical Information Deficit: Absence of gold-standard pathological diagnosis or core clinical endpoints required for model training/validations. 3. Comorbid Confounding Diseases: Presence of systemic diseases significantly affecting image interpretation (e.g., end-stage renal disease, active tuberculosis, severe autoimmune disorders) or major trauma/surgery history within the imaging field. 4. Synchronous/Metachronous Multiple Primary Cancers: Diagnosis of any non-study malignancy (excluding non-melanoma skin cancers) at enrollment to avoid interference with cancer-specific signal recognition. 5. Age Restrictions: For retrospective cohorts, individuals under 18 years old will be excluded to minimize physiological variability that may confound model performance. Prospective enrollment will follow protocol-specific age criteria. 6. Ethical and Compliance Exclusions: All personally identifiable information (PII) will be fully anonymized. Data failing anonymization standards or violating data-sharing agreements will be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Accuracy; | — |
Secondary
| Measure | Time frame |
|---|---|
| Sensitivity;Specificity; | — |
Countries
China
Contacts
Public ContactDong Xu
Zhejiang Cancer Hospital
Outcome results
None listed